1 Human mast cell tryptase appears to display considerable variation in activating proteinaseactivated receptor 2 (PAR 2 ). We found tryptase to be an ine cient activator of wild-type rat-PAR 2 (wt-rPAR 2 ) and therefore decided to explore the factors that may in¯uence tryptase activation of PAR 2 . 2 Using a 20 mer peptide (P20) corresponding to the cleavage/activation sequence of wt-rPAR 2 , tryptase was as e cient as trypsin in releasing the receptor-activating sequence (SLIGRL...). However, in the presence of either human-PAR 2 or wt-r PAR 2 expressing cells, tryptase could only activate PAR 2 by releasing SLIGRL from the P20 peptide, suggesting that PAR 2 expressed on the cells was protected from tryptase activation. 3 Three approaches were employed to test the hypothesis that PAR 2 receptor glycosylation restricts tryptase activation. (a) pretreatment of wt-rPAR 2 expressing cells or human embryonic kidney cells (HEK293) with vibrio cholerae neuraminidase to remove oligosaccharide sialic acid, unmasked tryptase-mediated PAR 2 activation. (b) Inhibiting receptor glycosylation in HEK293 cells with tunicamycin enabled tryptase-mediated PAR 2 activation. (c) Wt-rPAR 2 devoid of the Nterminal glycosylation sequon (PAR 2 T25 7 ), but not rPAR 2 devoid of the glycosylation sequon located on extracellular loop-2 (PAR 2 T224A), was selectively and substantially (430 fold) more sensitive to tryptase compared with the wt-rPAR 2 . 4 Immunocytochemistry using antisera that speci®cally recognized the N-terminal precleavage sequence of PAR 2 demonstrated that tryptase released the precleavage domain from PAR 2 T25 7 but not from wt-rPAR 2 . 5 Heparin : tryptase molar ratios of greater than 2 : 1 abrogated tryptase activation of PAR 2 T25 7 . 6 Our results indicate that glycosylation of PAR 2 and heparin-inhibition of PAR 2 activation by tryptase could provide novel mechanisms for regulating receptor activation by tryptase and possibly other proteases.